![]() | |
Names | |
---|---|
IUPAC name
7-{2'-[(1S,2E,4E)-1,6-Dimethyl-2,4-heptadienyl]
| |
Identifiers | |
3D model (
JSmol)
|
|
ChEBI | |
ChemSpider | |
ECHA InfoCard | 100.151.224 |
MeSH | Myxothiazol |
PubChem
CID
|
|
UNII | |
| |
| |
Properties | |
C25H33N3O3S2 | |
Molar mass | 487.68 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Myxothiazol is a chemical compound produced by the myxobacterium Myxococcus fulvus. It is an inhibitor of the mitochondrial cytochrome bc1 complex ( coenzyme Q - cytochrome c reductase). [1] [2]
Myxothiazol is a competitive inhibitor of ubiquinol, and binds at the quinol oxidation (Qo) site of the bc1 complex, blocking electron transfer to the Rieske iron-sulfur protein. Binding of myxothiazol induces a red-shift to the visible absorption spectrum of reduced haem bl. In contrast to stigmatellin, myxothiazol does not form a hydrogen bond to the Rieske iron-sulfur protein, binding instead in the 'b-proximal' region of the cytochrome b Qo site. Movement of the cytoplasmic domain of the Rieske protein is therefore unaffected by the binding of this inhibitor.[ citation needed]